Empowering pathologists as cancer precision medicine leaders: The Florida Society of Pathologists (FSP) Precision Medicine Academy (PMA) initiative.

e21013 Background: As cancer care increasingly relies on molecular and genomic biomarkers, pathologists play a central role in precision oncology. However, variability in access to structured education, emerging technologies, and interdisciplinary collaboration can limit consistent implementation. The Florida Society of Pathologists (FSP) launched the Precision Medicine Academy (PMA) to develop and implement a scalable, statewide strategy to educate and equip pathologists with the knowledge, skills, and confidence needed to lead precision medicine efforts. Methods: FSP designed a phased educational strategy informed by member needs, national guidelines, and stakeholder input. Phase 1 included a comprehensive continuing medical education (CME) curriculum delivered through live, virtual webinars. Academic pathologists, together with multidisciplinary care team members, delivered evidence-based information addressing foundational and emerging topics in precision oncology, including molecular and genomic biomarker testing, hereditary genetics and tumor genomics, multidisciplinary communication and collaboration strategies, digital pathology, bioinformatics, and AI in precision cancer diagnostics and treatment. Pre/post activity assessments measured knowledge changes and qualitative feedback captured perceived practice relevance. Results: Phase 1 successfully engaged pathologists from diverse practice settings across Florida. Learners demonstrated knowledge gains of 38.3%, 44.3%, 21.4%, 52.8%, and 50.5%, across key domains of cancer genetics, solid tumor biomarkers, hematologic malignancies, multidisciplinary collaboration, and digital pathology and AI, respectively. Qualitative feedback highlighted increased confidence in refining diagnostic workflows, improving communication with oncology and genetics colleagues, and leading the laboratory workforce to adopt precision medicine strategies. Participants emphasized the value of a pathology-focused, practice-relevant curriculum that addressed both technical and operational challenges. Conclusions: The FSP Precision Medicine Academy represents a society-led approach to building statewide capacity in precision oncology among pathologists. Phase 1 demonstrated that a CME-based curriculum can produce measurable knowledge gains and meaningful perceived practice benefits. Phase 2, launching in 2026, will expand this model through visiting rotations, virtual tumor boards, a multidisciplinary symposium, and facilitated peer exchange focusing on challenges and solutions in precision oncology. This initiative represents a significant step toward empowering pathologists as leaders in precision oncology and fostering a sustainable statewide learning community.